Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 6/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.44 |
| ▸ | ABL1 | P00519 | 3/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25347848 | 1.00 | MAP4K1 (0.44) | MAP4K1LRRK2ABL1GSK3BGSK3A | |
| SCHEMBL29513809 | 1.00 | MAP4K1 (0.44) | MAP4K1LRRK2ABL1GSK3BGSK3A | |
| SCHEMBL25346743 | 1.00 | MAP4K1 (0.44) | MAP4K1LRRK2ABL1GSK3BGSK3A | |
| SCHEMBL29513415 | 0.90 | MAP4K1 (0.44) | MAP4K1LRRK2ABL1FGFR4 | |
| SCHEMBL25347037 | 0.90 | MAP4K1 (0.44) | MAP4K1LRRK2ABL1FGFR4 | |
| SCHEMBL25344739 | 0.87 | GSK3B (0.56) | ABL1GSK3BGSK3AMAPK14 | |
| SCHEMBL29513749 | 0.87 | GSK3B (0.56) | ABL1GSK3BGSK3AMAPK14 | |
| SCHEMBL25346885 | 0.87 | GSK3B (0.41) | MAP4K1LRRK2ABL1GSK3BGSK3A | |
| SCHEMBL25347760 | 0.87 | GSK3B (0.41) | MAP4K1LRRK2ABL1GSK3BGSK3A | |
| SCHEMBL25346377 | 0.87 | GSK3B (0.41) | MAP4K1LRRK2ABL1GSK3BGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076973-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |